Johnson & Johnson’s schizophrenia drug Risperdal at Skenderian Apothecary in Cambridge, Massachusetts, on Jan. 23, 2007. Photo: JB Reed/Bloomberg News.
The Pennsylvania Supreme Court has ruled that the start date of the statute of limitations for bringing products liability claims over antipsychotic drug Risperdal must be determined by a jury following a factual analysis in each individual case.
In identical 6-1 decisions issued Nov. 20 in Saksek v. Janssen and Winter v. Janssen, the justices overturned a Superior Court ruling that granted summary judgment to Johnson & Johnson subsidiary Janssen and tossed out lawsuits filed by plaintiffs Jonathan Saksek and Joshua Winter—and, by extension, thousands of other plaintiffs—who alleged they developed excess breast tissue as a result of taking Risperdal.
